These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7758518)

  • 1. Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children.
    Benso L; Gambotto S; Pastorin L; Signorile F; Tanner JM
    Eur J Pediatr; 1995 Mar; 154(3):205-8. PubMed ID: 7758518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Growth velocity in thalassemic children receiving different protocols of chelating therapy].
    Elena MG; Fedele A; Gianino P; Giordanino S; Murru P; Tosi C; Vannelli S
    Minerva Pediatr; 1992; 44(1-2):41-2. PubMed ID: 1552875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
    Gomber S; Saxena R; Madan N
    Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of iron overload in thalassemia].
    Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
    Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F; Mautone A; Cavallo L; Altomare M; Montagna O; Dell'Edera L
    Acta Haematol; 1981; 66(2):96-101. PubMed ID: 6794319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
    Chan YL; Li CK; Pang LM; Chik KW
    Clin Radiol; 2000 Aug; 55(8):610-4. PubMed ID: 10964732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary function in thalassemic patients and the effect of chelation therapy.
    Vannasaeng S; Fucharoen S; Pootrakul P; Ploybutr S; Yansukon P
    Acta Endocrinol (Copenh); 1991 Jan; 124(1):23-30. PubMed ID: 1900379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
    Songdej D; Sirachainan N; Wongwerawattanakoon P; Sasanakul W; Kadegasem P; Sungkarat W; Chuansumrit A
    Acta Haematol; 2015; 133(2):226-36. PubMed ID: 25376266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: a comparative study.
    Soliman AT; elZalabany M; Amer M; Ansari BM
    J Trop Pediatr; 1999 Feb; 45(1):23-30. PubMed ID: 10191589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
    Girot R; Triadou P; Bories D; Jeannel F; Thevenin M; Rymer JC
    Nouv Rev Fr Hematol (1978); 1982; 24(5):281-7. PubMed ID: 7167380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 20. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.